MHMichael Hartmann

Michael Hartmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Hartmann has a total of 249 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reducing medication errors in neurosurgery through clinical pharmacy interventions: a prospective observational study

    by Aaron Lawson McLean, Anna Schlattl, Christian Senft, Michael Hartmann, Falko Schwarz

    Neurosurgical patient care is inherently complex, characterized by high rates of polypharmacy, advanced age, and significant comorbidities, all of which increase the risk of medication errors. These challenges are compounded by dynamic treatment plans and intensive care demands. In response, clinical pharmacist-led “pharmaceutical interventions” have emerged as a promising strategy to enhance medication safety. This study aimed to evaluate the impact of a structured weekly pharmacist-led medication review programme on prescribing practices and patient outcomes in a tertiary academic neurosurgical department. In this 12-month prospective study, a pharmacist performed weekly medication reviews on the neurosurgical ward and HDU. Interventions were coded in ADKA-DokuPIK and relayed to the team; 10% were re-audited to confirm uptake. The year was split into two six-month epochs to assess temporal trends. Administrative data from the intervention year were compared with a historical control for length of stay (LOS) and in-hospital mortality. Adverse-drug-event rates were not prospectively collected. A total of 996 interventions were documented among 1795 patients (0.55/patient). Intervention rates declined from 0.7 to 0.4 per patient between periods ( p = 0.016), suggesting a learning effect. Implementation of recommendations was confirmed in 78% of audited cases. The most commonly affected drugs were pantoprazole ( n = 77), amlodipine ( n = 47), ciprofloxacin ( n = 44). Median LOS decreased from 8.1 to 7.3 days ( p = 0.032), the proportion of prolonged hospitalisations (> 14 days) fell from 18.9% to 14.8% ( p = 0.002), and in-hospital mortality declined from 4.6% to 3.0% ( p = 0.014). Routine integration of a clinical pharmacist into neurosurgical care was associated with fewer medication-related issues, measurable improvements in LOS and mortality, and evidence of progressive prescriber adaptation. These findings support broader implementation of pharmacist-led interventions in high-risk surgical environments. Controlled multicenter trials are warranted.


  • Open Access

    Impact of Antibiotic Therapy on the Upper Respiratory Tract and Gut Mycobiome in Patients with Cystic Fibrosis

    by Cristina Zubiria-Barrera, Malena Bos, Robert Neubert, Jenny Fiebig, Michael Lorenz, Michael Hartmann, Jochen G. Mainz, Hortense Slevogt, Tilman E. Klassert

    Patients with cystic fibrosis (CF) are frequently exposed to antibiotic treatments, which can alter the fungal communities (mycobiome) across their mucosal sites. This pilot study investigated the impact of antibiotic exposure on the mycobiome by analyzing fungal community dynamics in the upper respiratory- (nasal lavage) and gastrointestinal- (stool samples) tracts of 12 patients with CF following (a) long-term antibiotic treatment over a three-year period and (b) short-term antibiotic therapy during acute pulmonary exacerbations. Mycobiome profiles of the samples obtained from 38 healthy individuals were also analyzed and used for comparison purposes. The ITS1 region of the fungal rRNA gene cluster was sequenced to characterize and quantify the fungal community composition in both cohorts. Compared to healthy controls, samples from the patients with CF who had undergone long-term antibiotic treatment revealed a significantly increased fungal biomass in both sino-nasal and stool samples. Moreover, diversity metrics revealed significant differences in nasal lavage samples, whereas the stool samples showed no significant variation. Candida spp. was significantly enriched in both nasal and stool samples from CF patients. Further analyses demonstrated a strong positive correlation between the relative abundance of Candida spp. and the cumulative antibiotic intake over the three-year period in sino-nasal samples, but not in stool samples. Acute antibiotic treatment during a pulmonary exacerbation episode also led to a marked increase in the abundance of Candida spp. in sino-nasal samples. These findings highlight the increased sensitivity of the sino-nasal mycobiome to both chronic and acute antibiotic exposure in CF patients, as characterized by a site-specific fungal overgrowth, particularly of Candida spp.


  • Open Access

    Characteristics of patients hospitalized for falls: electronic health records analysis

    by Anna Kathrin Schuster, Miriam Kesselmeier, Laura Weisbach, Christoph Stumme, Wilhelm Behringer, Michael Hartmann, Katrin Farker

    Aim: Falls are common adverse events, often leading to hospitalization with adverse effects on the physiological and psychological health of patients. Although risk factors for falls are well examined, it is difficult to identify fallers through their electronical health records (EHR). This study investigates whether EHR contain characteristics that indicate a fall before hospitalization. Subject and methods: We evaluated 500 EHR of patients hospitalized through the Department of Emergency Medicine of Jena University Hospital. We considered electronically available characteristics including free texts and ICD-10-GM codes. Inpatients with and without a fall event previous to their hospitalization were compared for significant differences in EHR characteristics. Therefore, we applied the Mann–Whitney U test and the exact Fisher test, respectively, with a two-sided significance level of 0.05 and without correction for multiple testing. Results: It was possible to identify significant differences between fallers and non-fallers by gender (66.3% women), age (median: 84 years), living situation prior to hospital admission (20.5% from nursing home, 41.1% living alone) and type of discharge. Besides other risk factors, ICD-10-GM codes included injuries, especially fractures and superficial injuries, but also cognitive deficits, incontinence, and physical limitations were more prevalent with fallers than non-fallers. Conclusion: This study identified characteristics that can support identification of fall patients through EHR. Such information should be tested in other hospitals and is expected to enhance patient safety and utilization of healthcare resources.

  • Open Access

    Experience with PCR Testing for Enteric Bacteria and Viruses of Emergency Department Patients with Acute Gastroenteritis: Are There Implications for the Early Treatment of Clostridioides difficile Infection?

    by Andreas Iffland, Maria Zechel, Jan-Christoph Lewejohann, Birgit Edel, Stefan Hagel, Michael Hartmann, Bettina Löffler, Jürgen Rödel

    Early identification of acute gastroenteritis (AGE) pathogens via PCR may improve the management of patients presenting to the emergency department (ED). In this study, we evaluated the implementation of a testing algorithm for ED patients with AGE using the BD MAX automated PCR system. Data from 133 patients were analyzed. A total of 56 patients (42%) tested positive via PCR for at least one bacterial or viral pathogen. The median time to report PCR results was 6.17 h compared to 57.28 h for culture results for bacterial pathogens. The most common pathogen was Clostridioides difficile (n = 20, 15%). In total, 14 of the 20 C. difficile-positive patients were aged >65 years and 17 of the 20 patients (85%) were diagnosed with a clinically relevant infection based on typical symptoms and laboratory values. They received antibiotics, mostly oral vancomycin, starting a median of 11.37 h after ED admission. The introduction of PCR for the diagnosis of AGE infection in patients presenting to the ED may have the greatest impact on the rapid identification of C. difficile and the timely administration of antibiotics if necessary.


  • Open Access

    Inconsistencies of absolute drug–drug contraindication reports: Analysis of Summaries of Product Characteristics of commonly prescribed drugs

    by Laura Weisbach, Anna K. Schuster, Michael Hartmann, Pauline Dürr, Melanie I. Then, Wahram Andrikyan, Martin F. Fromm, Renke Maas, Katrin Farker

    Aims: Prescribing information should follow a defined structure to help prescribers easily find required information. Often information appears in different sections of Summaries of Product Characteristics (SmPCs) in an inconsistent way. Still unknown is how this inconsistency affects absolute contraindications and how it can be improved. Thisstudy aimed to evaluate the structure of absolute contraindications in SmPCs based on absolute drug–drug contraindications (DDCI) in the section ‘contraindications’ and references to sections ‘special warnings and precautions for use’ (here as ‘warnings’) and ‘interaction with other medicinal products and other forms of interaction’ (here as ‘interactions’).Methods: SmPCs of 693 commonly prescribed drugs were analysed regarding absolute DDCI in ‘contraindications’ sections. References to sections on ‘warnings’ and ‘interactions’ were evaluated to characterize information provided about DDCI.Results: Of 693 analysed SmPCs, 138 (19.9%) contained ≥1 absolute DDCI. Of 178 SmPCs that referred to sections on ‘warnings’ or ‘interactions’, 131 (73.6%) did not contain further information on absolute DDCI, whereas 47 (26.4%) did. Such additional information was found in sections on ‘interactions’ and ‘warnings’ in 41 (87.2%) and 9 (19.1%) SmPCs, respectively.Conclusions: Information regarding absolute DDCI was found not only in sections on ‘contraindications’ but also in sections on ‘warnings’ and ‘interactions’. Information was not given with consistently straightforward phrasing and structure and so can leave uncertainty for prescribers. To improve drug safety, clear definitions and wording for absolute and relative contraindications should be provided, ideally in tables.


  • Open Access

    Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany

    by Florian Schwarz, Habibollah Arefian, Michael Hartmann, Ingo Runnebaum

    This study evaluated factors that influence the cost-effectiveness of talazoparib, particularly for patients with a germline breast-cancer-gene-(brca)-mutation and locally advanced or metastasized breast cancer within the context of the German healthcare system. We constructed a partitioned survival model to compare medical costs and treatment effectiveness for patients with such cancers over 45 months. Transition probabilities were derived from survival data from a randomized Phase-III EMBRACA trial, utilities based on published reports, and costs in Euros, which included costs for drug acquisition, clinical monitoring, and treatment of adverse events. Willingness-to-pay thresholds were set to be multiples of the current German per capita gross domestic product. Treatment with talazoparib led to a gain of 0.32 life-years (0.22 quality-adjusted life-years). The mean total cost of €84,003 for talazoparib and €12,741 for standard therapy resulted in an incremental cost-effectiveness ratio of €223,246 per life-year and €323,932 per quality-adjusted life-year gained, indicating that talazoparib is unlikely to be cost-effective at current pricing.


  • Open Access

    Inconsistencies and Ambiguities in Liver-Disease-Related Contraindications—A Systematic Analysis of SmPCs/PI of Major Drug Markets

    by Laura Weisbach, Anna K. Schuster, Michael Hartmann, Martin F. Fromm, Renke Maas, Katrin Farker

    Liver disease is a common condition worldwide that can cause alterations in drug disposition and susceptibility to drug toxicities, with increased risk of adverse drug reactions. European Summaries of Product Characteristics (SmPCs) and United States Prescribing Information (US PI) should therefore be comprehensible to prescribers regarding their liver-associated contraindications to ensure safe prescribing. This study aimed to evaluate the ambiguity of terminology used in communicating liver-associated absolute contraindications in SmPCs/PI of commonly prescribed drugs in four major drug markets (Germany, Switzerland, the United Kingdom, and the United States) by assigning wordings to different categories and analyzing their clinical comprehensibility. For US PI, 79% did not contain liver-related contraindications, compared to 2, 13, and 6% of German, Swiss, and British SmPCs, respectively. Study findings indicate that out of 228 examined SmPCs/PI containing liver-related contraindications, 77, 79, 76, and 52% contained unclear wording in the German, Swiss, British, and American drug market, respectively. Only 40% (German), 52% (Swiss), 39% (British), and 29% (American) of SmPCs/PI included terms with explicit wording. Including more precise statements in SmPCs/PI based on laboratory parameters (such as albumin) or scores (e.g., the Child–Pugh score) to objectify the severity of liver disease may improve the clarity of SmPCs/PI and the safety of drug prescription.


  • Open Access

    Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial

    by Andreas Stallmach, Philip Grunert, Johannes Stallhofer, Bettina Löffler, Michael Baier, Jürgen Rödel, Michael Kiehntopf, Sophie Neugebauer, Dietmar H. Pieper, Howard Junca, et al.

    Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with significant morbidity and mortality. Although the precise cause remains unknown, disturbances in the intestinal microbial community have been linked to its pathogenesis. Randomized controlled trials in UC and relapsing Clostridioides difficile infection (CDI) have established fecal microbiota (FM) transfer (FMT) as an effective therapy. In this context, preliminary results indicated that the transfer of sterile fecal microbiota filtrates (<0.2 μm; FMF, FMFT) of donor stool also drives gastrointestinal microbiota changes and eliminates symptoms in CDI patients. However, along with the success of FMT, regulatory agencies issued safety alerts following reports of serious adverse events due to transmission of enteric pathogens through FMT. To reduce this risk, we established an extensive test protocol for our donors and quarantine regulations for the produced capsules, but alternative concepts are desirable. Methods: Our project is a randomized, controlled, longitudinal, prospective, three-arm, multicenter, double-blind study to determine the safety and efficacy of repeated long-term, multi-donor FM or FMF transfers compared to placebo using oral, frozen capsules in 174 randomized patients with mild to moderate active UC. The primary outcome will be clinical remission at week 12. Discussion: This proposal aims to examine (a) the efficacy of encapsulated transfer of FM and FMF as a therapy for mild to moderate UC, (b) the short- and long-term safety of FMT and FMFT in patients with UC, and (c) the microbial and immunologic changes that occur after FMT and FMFT to help understand how and why it affects inflammatory bowel disease. Trial registration: ClinicalTrials.gov NCT03843385. DRKS (Deutsches Register für Klinische Studien) DRKS00020471


  • Open Access

    Healthcare Utilization and Costs in Sepsis Survivors in Germany–Secondary Analysis of a Prospective Cohort Study

    by Konrad F. R. Schmidt, Katharina Huelle, Thomas Reinhold, Hallie C. Prescott, Rebekka Gehringer, Michael Hartmann, Thomas Lehmann, Friederike Mueller, Konrad Reinhart, Nico Schneider, et al.

    Background: Survivors of sepsis often face long-term sequelae after intensive care treatment. Compared to the period of hospitalization, little is known about the ambulatory healthcare utilization in sepsis patients. The study evaluated healthcare utilization and associated costs of sepsis care including allied health professions after initial hospitalization. Methods: Secondary analysis was performed on data in 210 sepsis patients prospectively enrolled from nine intensive care study centers across Germany. Data was collected via structured surveys among their Primary care (Family-) physicians (PCPs) within the first month after discharge from ICU (baseline) and again at 6, 12 and 24 months after discharge, each relating to the period following the last survey. Costs were assessed by standardized cost unit rates from a health care system’s perspective. Changes in healthcare utilization and costs over time were calculated using the Wilcoxon rank-sum test. Results: Of the 210 patients enrolled, 146 (69.5%) patients completed the 24 months follow-up. In total, 109 patients were hospitalized within the first 6 months post-intensive care. Mean total direct costs per patient at 0–6 months were €17,531 (median: €6047), at 7–12 months €9029 (median: €3312), and at 13–24 months €18,703 (median: €12,828). The largest contributor to the total direct costs within the first 6 months was re-hospitalizations (€13,787 (median: €2965). After this first half year, we observed a significant decline in inpatient care costs for re-hospitalizations (p ≤ 0.001). PCPs were visited by more than 95% of patients over 24 months. Conclusions: Sepsis survivors have high health care utilization. Hospital readmissions are frequent and costly. Highest costs and hospitalizations were observed in more than half of patients within the first six months post-intensive care. Among all outpatient care providers, PCPs were consulted most frequently. Clinical impact: Sepsis survivors have a high healthcare utilization and related costs which persist after discharge from hospital. Within outpatient care, possible needs of sepsis survivors as physiotherapy or psychotherapy seem not to be met appropriately. Development of sepsis aftercare programs for early detection and treatment of complications should be prioritized.